Enanta Pharmaceuticals (ENTA) posts Q3 2026 loss while pushing RSV and immunology drugs forward
Rhea-AI Filing Summary
Enanta Pharmaceuticals, Inc. reported fiscal third quarter 2026 results, reflecting a clinical-stage company investing heavily in virology and immunology while posting continued losses. Revenue for the quarter was $14.4 million, all from royalties on AbbVie’s HCV regimen MAVYRET®/MAVIRET®, down from $18.3 million a year earlier due to lower HCV sales.
Research and development expenses fell to $22.1 million and general and administrative expenses to $9.5 million, helping limit the quarterly net loss to $19.5 million, or $0.67 per diluted share. Cash, cash equivalents and marketable securities totaled $211.5 million at June 30, 2026, and the company expects this, along with retained royalties, to fund operations into fiscal 2029. Enanta highlighted progress in its RSV program, including dosing initiation in the Phase 2b pediatric LOTUS trial of zelicapavir and preparation for RESOLVE, a registrational Phase 2b/3 trial in high-risk adults, with topline data from both expected in 2027. It also advanced immunology candidates EDP-978 (KIT inhibitor), EPS-3903 (STAT6 inhibitor) and MRGPRX2-targeting compounds, and noted European Commission approval of MAVIRET for acute HCV, which supports ongoing royalty revenue.
Positive
- Cash runway into fiscal 2029 supported by $211.5 million in cash and marketable securities plus retained royalties provides multi‑year funding visibility for current programs.
- Zelicapavir advanced to registrational development with a Phase 2b pediatric trial underway and a Phase 2b/3 high‑risk adult trial planned, creating multiple RSV data catalysts in 2027.
Negative
- Quarterly revenue fell to $14.4 million from $18.3 million year over year, reflecting lower AbbVie HCV product sales.
- Net loss remained substantial at $19.5 million for the quarter and $44.5 million for the first nine months of fiscal 2026.
- Interest expense more than doubled to $4.1 million in the quarter due to the liability from the royalty sale transaction.
Filing Explained
Enanta’s ongoing HCV royalty cash carries a 54.5% payment obligation to OMERS through June 30, 2032.
This Form 8-K reports Enanta Pharmaceuticals’ completed fiscal third-quarter results for the period ended
The royalty sale is accounted for as debt: Enanta records all royalty revenue, but
The Pfizer patent dispute is not complete: the Federal Circuit affirmed invalidity of the patent claims, Enanta filed a combined rehearing petition in July, and a Unified Patent Court hearing is scheduled for
8-K Event Classification
Key Figures
Key Terms
royalty sale transaction financial
registrational Phase 2b/3 trial medical
Fast Track designation regulatory
IND-enabling activities regulatory
non-canonical G-Protein-Coupled-Receptor (GPCR) medical
Earnings Snapshot
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
How much revenue did Enanta (ENTA) generate in its fiscal Q3 2026?
What was Enanta’s (ENTA) net loss and EPS for fiscal Q3 2026?
What is Enanta’s (ENTA) cash position and runway as of June 30, 2026?
What are the key RSV program milestones disclosed by Enanta (ENTA)?
Which immunology programs is Enanta (ENTA) advancing and what are the timelines?
How does the royalty sale transaction affect Enanta’s (ENTA) financials?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
|
Not Applicable |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 10, 2026, Enanta Pharmaceuticals, Inc. announced via press release its results for the fiscal quarter ended June 30, 2026. A copy of Enanta's press release is hereby furnished to the Commission and incorporated by reference herein as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
Exhibit Number |
Description |
99.1 |
Press Release of Enanta Pharmaceuticals, Inc. dated August 10, 2026, reporting Enanta's financial results for the fiscal quarter ended June 30, 2026 |
104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
ENANTA PHARMACEUTICALS, INC. |
|
|
|
|
Date: |
August 10, 2026 |
By: |
/s/ Jay R. Luly, Ph.D. |
|
|
|
Jay R. Luly, Ph.D. |
Exhibit 99.1
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026
WATERTOWN, Mass., August 10, 2026 – Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal third quarter ended June 30, 2026.
“During the quarter, we continued to build momentum across both our RSV and immunology programs,” said Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta. “Dosing began in LOTUS, our Phase 2b trial of zelicapavir in pediatric patients with RSV in Thailand, with topline data anticipated in 2027. We also announced plans to advance zelicapavir into a registrational Phase 2b/3 trial in high-risk adults with RSV and remain on track to initiate this study, RESOLVE, in the fourth quarter, with initial Phase 2b data expected next year. With no approved antiviral therapies currently available for RSV, we believe zelicapavir is uniquely positioned to address a substantial unmet need across both high-risk adult and pediatric populations. We continue to execute our clinical development plan and aim to deliver what could become the first approved antiviral treatment for RSV. Additionally, in immunology, we are focused on reporting topline data from our Phase 1 study of EDP-978 in the fourth quarter of 2026, while also advancing EPS-3903, our oral, once-daily STAT6 inhibitor, toward an IND filing this year. Further, we are on track to select an MRGPRX2 development candidate in the second half of 2026. With a catalyst rich year ahead, we have multiple opportunities to drive shareholder value and bring important treatments to patients in need.”
Fiscal Third Quarter Ended June 30, 2026 Financial Results
Total revenue for the three months ended June 30, 2026 was $14.4 million and consisted of royalty revenue from worldwide net sales of AbbVie’s hepatitis C virus (HCV) regimen MAVYRET®/MAVIRET® (glecaprevir/pibrentasvir), compared to $18.3 million for the three months ended June 30, 2025. The decrease in revenue is primarily due to AbbVie’s lower reported HCV sales as compared to the same period in 2025.
A portion (54.5%) of Enanta’s ongoing royalty revenue from AbbVie’s net sales of MAVYRET®/MAVIRET® is paid to OMERS, one of Canada’s largest defined benefit pension plans, pursuant to a royalty sale transaction affecting royalties earned after June 2023. For financial reporting purposes, the transaction was treated as debt, with the upfront purchase payment of $200.0 million recorded as a liability. Each quarter, Enanta records 100% of the royalty earned as revenue and then amortizes the debt liability proportionally as 54.5% of the cash royalty payments are paid to OMERS through June 30, 2032, subject to a cap of 1.42 times the purchase price, after which point 100% of the cash royalty payments will be retained by Enanta. Interest expense was $4.1 million for the three months ended June 30, 2026, as compared to $1.6 million for the period ended June 30, 2025. The increase was due to the increase in forecasted royalty revenue from AbbVie’s net sales of MAVYRET®/MAVIRET®.
Research and development expenses totaled $22.1 million for the three months ended June 30, 2026, compared to $27.2 million for the three months ended June 30, 2025. The decrease was due to a decrease in clinical trial expenses for Enanta’s RSV programs, partially offset by increased costs associated with the Company’s immunology programs.
General and administrative expenses totaled $9.5 million for the three months ended June 30, 2026, compared to $10.0 million for the three months ended June 30, 2025. The decrease was primarily due to a decrease in stock-based compensation expenses.
Interest and investment income, net, totaled $1.9 million for the three months ended June 30, 2026, compared to $2.3 million for the three months ended June 30, 2025. The decrease in interest and investment income was due to lower interest rates year over year.
Enanta recorded an income tax expense of less than $0.1 million for the three months ended June 30, 2026 compared to an income tax expense of less than $0.1 million for the three months ended June 30, 2025.
Net loss for the three months ended June 30, 2026 was $19.5 million, or a loss of $0.67 per diluted common share, compared to a net loss of $18.3 million, or a loss of $0.85 per diluted common share, for the corresponding period in 2025.
Enanta’s cash, cash equivalents and short-term and long-term marketable securities totaled $211.5 million at June 30, 2026. Enanta expects that its current cash, cash equivalents and marketable securities, as well as its retained portion of future royalty revenue, will be sufficient to meet the anticipated cash requirements of its existing business and development programs into fiscal 2029.
Virology
Enanta’s virology pipeline includes the leading portfolio of RSV treatments in clinical development, consisting of zelicapavir, a once-daily N-protein inhibitor, and EDP-323, a once-daily L-protein inhibitor, both of which received Fast Track designation from the U.S. Food and Drug Administration (FDA).
Immunology
Enanta’s immunology pipeline is focused on designing and developing highly potent and selective oral inhibitors for the treatment of inflammatory diseases, by targeting key drivers of the type 2 immune response.
Corporate
About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and immunological diseases. In virology, Enanta’s clinical programs are focused on the development of first-in-disease and best-in-disease treatments for respiratory syncytial virus (RSV). The Company’s immunology pipeline
aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, with KIT, STAT6 and MRGPRX2 inhibition.
Glecaprevir, a protease inhibitor discovered by Enanta, is part of the only treatment approved for curing both acute and chronic hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information.
Forward-Looking Statements
This press release contains forward-looking statements, including statements with respect to the timeline and prospects for advancement of Enanta’s clinical programs in RSV and KIT inhibition and its preclinical immunology programs, including its programs targeting STAT6 and MRGPRX2 inhibition. Statements that are not historical facts are based on management’s current expectations, estimates, forecasts and projections about Enanta’s business and the industry in which it operates and management’s beliefs and assumptions. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors and risks that may affect actual results include: the impact of development, regulatory and marketing efforts of others with respect to vaccines and competitive treatments for RSV; the discovery and development risks of Enanta’s programs in virology and immunology; Enanta’s limited clinical development experience; Enanta’s ability to partner its RSV or other programs; Enanta’s need to attract and retain senior management and key research and development personnel; Enanta’s need to obtain and maintain patent protection for its product candidates and avoid potential infringement of the intellectual property rights of others; the outcome of the Federal Circuit rehearing petition and the Unified Patent Court proceedings related to Enanta’s patent claim against Pfizer; and other risk factors described or referred to in “Risk Factors” in Enanta’s Form 10-K for the fiscal year-ended September 30, 2025, and any other periodic reports filed more recently with the Securities and Exchange Commission. Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Enanta undertakes no obligation to update or revise these statements, except as may be required by law.
###
Media and Investors Contact:
Jennifer Viera
jviera@enanta.com
Tables to Follow
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
ENANTA PHARMACEUTICALS, INC. |
|
||||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS |
|
||||||||||||||||
UNAUDITED |
|
||||||||||||||||
(in thousands, except per share amounts) |
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
||||||||||
|
|
|
June 30, |
|
|
June 30, |
|
||||||||||
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Revenue |
$ |
14,359 |
|
|
$ |
18,314 |
|
|
$ |
50,133 |
|
|
$ |
50,199 |
|
||
Operating expenses |
|
|
|
|
|
|
|
|
|
|
|
||||||
Research and development |
|
22,126 |
|
|
|
27,210 |
|
|
|
62,428 |
|
|
|
82,931 |
|
||
General and administrative |
|
9,469 |
|
|
|
9,997 |
|
|
|
28,046 |
|
|
|
34,231 |
|
||
Total operating expenses |
|
31,595 |
|
|
|
37,207 |
|
|
|
90,474 |
|
|
|
117,162 |
|
||
Loss from operations |
|
(17,236 |
) |
|
|
(18,893 |
) |
|
|
(40,341 |
) |
|
|
(66,963 |
) |
||
Interest expense |
|
|
|
(4,130 |
) |
|
|
(1,618 |
) |
|
|
(10,529 |
) |
|
|
(5,294 |
) |
Interest and investment income, net |
|
1,901 |
|
|
|
2,285 |
|
|
|
6,407 |
|
|
|
7,376 |
|
||
Loss before income taxes |
|
(19,465 |
) |
|
|
(18,226 |
) |
|
|
(44,463 |
) |
|
|
(64,881 |
) |
||
Income tax (expense) benefit |
|
(36 |
) |
|
|
(29 |
) |
|
|
(67 |
) |
|
|
1,692 |
|
||
Net loss |
$ |
(19,501 |
) |
|
$ |
(18,255 |
) |
|
$ |
(44,530 |
) |
|
$ |
(63,189 |
) |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net loss per share |
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Basic |
$ |
(0.67 |
) |
|
$ |
(0.85 |
) |
|
$ |
(1.54 |
) |
|
$ |
(2.96 |
) |
|
|
Diluted |
$ |
(0.67 |
) |
|
$ |
(0.85 |
) |
|
$ |
(1.54 |
) |
|
$ |
(2.96 |
) |
|
Weighted average common shares outstanding |
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Basic |
|
29,090 |
|
|
|
21,377 |
|
|
|
28,958 |
|
|
|
21,322 |
|
|
|
Diluted |
|
29,090 |
|
|
|
21,377 |
|
|
|
28,958 |
|
|
|
21,322 |
|
|
ENANTA PHARMACEUTICALS, INC. |
|
|||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS |
|
|||||||||
UNAUDITED |
|
|||||||||
(in thousands) |
|
|||||||||
|
|
|
|
|
|
|
|
|
||
|
|
|
|
June 30, |
|
|
September 30, |
|
||
|
|
|
|
2026 |
|
|
2025 |
|
||
Assets |
|
|
|
|
|
|||||
Current assets |
|
|
|
|
|
|||||
|
Cash and cash equivalents |
$ |
33,419 |
|
|
$ |
32,298 |
|
||
|
Short-term marketable securities |
|
156,087 |
|
|
|
156,566 |
|
||
|
Accounts receivable |
|
6,534 |
|
|
|
6,882 |
|
||
|
Prepaid expenses and other current assets |
|
7,579 |
|
|
|
8,590 |
|
||
|
|
Total current assets |
|
203,619 |
|
|
|
204,336 |
|
|
Long-term marketable securities |
|
21,987 |
|
|
|
— |
|
|||
Property and equipment, net |
|
31,942 |
|
|
|
35,395 |
|
|||
Operating lease, right-of-use assets |
|
35,852 |
|
|
|
37,549 |
|
|||
Long-term restricted cash |
|
3,360 |
|
|
|
3,360 |
|
|||
Other long-term assets |
|
110 |
|
|
|
92 |
|
|||
|
|
Total assets |
$ |
296,870 |
|
|
$ |
280,732 |
|
|
Liabilities and Stockholders' Equity |
|
|
|
|
|
|||||
Current liabilities |
|
|
|
|
|
|||||
|
Accounts payable |
$ |
3,293 |
|
|
$ |
1,948 |
|
||
|
Accrued expenses and other current liabilities |
|
10,183 |
|
|
|
12,751 |
|
||
|
Liability related to the sale of future royalties |
|
36,784 |
|
|
|
30,710 |
|
||
|
Operating lease liabilities |
|
3,906 |
|
|
|
3,146 |
|
||
|
|
Total current liabilities |
|
54,166 |
|
|
|
48,555 |
|
|
Liability related to the sale of future royalties, net of current portion |
|
88,289 |
|
|
|
111,132 |
|
|||
Operating lease liabilities, net of current portion |
|
51,750 |
|
|
|
54,757 |
|
|||
Series 1 nonconvertible preferred stock |
|
1,311 |
|
|
|
1,311 |
|
|||
Other long-term liabilities |
|
286 |
|
|
|
260 |
|
|||
|
|
Total liabilities |
|
195,802 |
|
|
|
216,015 |
|
|
Total stockholders' equity |
|
101,068 |
|
|
|
64,717 |
|
|||
|
|
Total liabilities and stockholders' equity |
$ |
296,870 |
|
|
$ |
280,732 |
|
|
|
|
|
|
|
|
|
|
|
||